dexamethasone + morphine + midazolam

This is a combination of three pharmaceutical agents commonly used in palliative care and pain management settings: - **Dexamethasone** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressant properties. It acts primarily by binding to the glucocorticoid receptor, modulating gene expression to suppress inflammation and immune responses. - **Morphine** is an opioid analgesic that exerts its effects mainly through agonism at the mu-opioid receptor in the central nervous system, providing significant pain relief. - **Midazolam** is a short-acting benzodiazepine that enhances GABAergic neurotransmission by acting as a positive allosteric modulator at the GABA-A receptor. It provides sedation, anxiolysis, amnesia, and muscle relaxation. This combination may be used for symptom control in advanced disease or end-of-life care (e.g., for severe pain with anxiety or agitation). However, compatibility issues have been reported when mixing these drugs together in syringe drivers or infusion solutions; specifically, combinations containing dexamethasone and midazolam can result in chemical instability[1][2][3]. Clinical use should be guided by compatibility data and close monitoring.

Other names

dexamethasonemorphinemidazolam